PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 17, 2026Clinical & Translational Oncology0 citationsOpen Access

FAT4 loss promotes tumor growth and ferroptosis resistance in hepatocellular carcinoma via PI3K/AKT pathway activation

View Full Paper
JLJing LiJiangnan UniversityJSJialing SunGuangzhou University of Chinese MedicineRHRui HuGuangzhou University of Chinese Medicine

Key Points

  • This research aims to investigate the role of FAT4 in ferroptosis resistance and tumor growth in hepatocellular carcinoma.
  • Examined expression levels of FAT4, GPX4, and SLC7A11 in HCC cells.
  • Investigated the impact of FAT4 loss on PI3K/AKT signaling.
  • Analyzed ferroptosis sensitivity in relation to FAT4 expression.
  • FAT4 loss was linked to increased tumor growth in HCC.
  • Decreased GPX4 and SLC7A11 expression were observed with FAT4 loss.
  • FAT4 suppression resulted in enhanced resistance to ferroptosis through PI3K/AKT pathway activation.

Abstract

FAT4 may enhance ferroptosis sensitivity in HCC by suppressing GPX4 and SLC7A11 expression, potentially by inhibiting PI3K/AKT signaling. Thus, this study presents FAT4 as a biomarker associated with tumor progression and a potential determinant for overcoming ferroptosis resistance in HCC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Li et al. (2026) studied this question.

synapsesocial.com/papers/69b8ef52deb47d591b8c5574https://doi.org/10.1007/s12094-026-04302-y
Ask AI
Helpful
Bookmark
Share
View Full Paper